Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1230-1233

  Yokoseki, Akiko ^a   Saji, Etsuji ^a   Arakawa, Musashi ^a   Hokari, Mariko ^a   Ishiguro, Takanobu ^a   Yanagimura, Fumihiro ^a   Ishihara, Tomohiko ^a   Okamoto, Kouichirou ^a   Nishizawa, Masatoyo ^a   Kawachi, Izumi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

CCR7; compartmentalized immune response; CSF; Fingolimod; multiple sclerosis

Indexed keywords

AQUAPORIN 4 ANTIBODY; BETA1A INTERFERON; CHEMOKINE RECEPTOR CCR7; FINGOLIMOD; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; OLIGOCLONAL BAND;

ADULT; ARTICLE; BRAIN DAMAGE; CASE REPORT; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; DISEASE SEVERITY; DRUG SUBSTITUTION; HUMAN; IMMUNOFLUORESCENCE; INJECTION SITE REACTION; MALE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PHENOTYPE; PLEOCYTOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN ABSCESS; SPASTIC GAIT; SPINAL CORD LESION; T LYMPHOCYTE; TREATMENT DURATION;

CCR7; COMPARTMENTALIZED IMMUNE RESPONSE; CSF; FINGOLIMOD; MULTIPLE SCLEROSIS;

BRAIN; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RECEPTORS, CCR7; SPHINGOSINE; YOUNG ADULT;

EID: 84881081081     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513481395     Document Type: Article

References (10)

1. Steinman L. Multiple sclerosis: A two-stage disease. Nat Immunol. 2001 ; 2: 762-764
2. Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011 ; 76: 1214-1221
3. Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?. Neurology. 2012 ; 78: 928-930
4. Daelman L, Maitrot A, Maarouf A, et al. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012 ; 18: 1647-1649
5. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. The N Engl J Med. 2006 ; 355: 1124-1140
6. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology. 2009 ; 73: 1628-1637
7. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009 ; 9: 393-407
8. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010 ; 75: 403-410
9. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 ; 71: 1261-1267
10. Kivisakk P, Mahad DJ, Callahan MK, et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. Ann Neurol. 2004 ; 55: 627-638